Hyatt Regency Huntington Beach Resort and Spa
Grand Ballroom
21500 Pacific Coast Highway
Huntington Beach, California, 92648
Rheumatologists, advanced practice providers who work with these specialists, and other healthcare providers who contribute to the management of patients with Sjögren’s disease
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this live material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of Continuing Pharmacy Education Credit (UAN# JA4008190-0000-26-007-L01-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Hyatt Regency Huntington Beach Resort and Spa
Grand Ballroom
21500 Pacific Coast Highway
Huntington Beach, California, 92648
For all CE inquiries or special needs, please contact admin@academiccme.com.
Discuss the updated understanding of pathophysiology, screening, diagnosis, and therapeutic targets of Sjögren’s disease
Analyze the most up to date evidence for B-cell depleting therapies, including that of a novel dual mechanism B-cell depletor and BAFF-R inhibitor, to improve the management of patients with Sjögren’s disease
Review the potential role of DMT with novel B-cell depleting and dual mechanism therapies to improve patient quality of life and reduce disease burden in Sjögren’s disease
|
I. Update on Sjögren's Disease
a.Pathophysiology and Therapeutic Targets
b.Strategies for Screening and Diagnosis
c.Review of Current Sjögren's Disease Therapies and Unmet Patient Needs
d.Analysis of Dual Mechanism B-cell Depleting/BAFF-R Inhibiting Monoclonal Antibodies
|
|
II. Clinical Trial Data for Novel and Emerging Therapies for the Management of Patients With Sjögren's Disease
|
|
III. Advances in Individualized Treatment Plans to Improve Outcomes in Patients With Sjögren's Disease
a.Symptom Management
b.Assessing and Monitoring Disease Progression and Impact on Patient QoL
|
|
I. Update on Sjögren's Disease
a.Pathophysiology and Therapeutic Targets
b.Strategies for Screening and Diagnosis
c.Review of Current Sjögren's Disease Therapies and Unmet Patient Needs
d.Analysis of Dual Mechanism B-cell Depleting/BAFF-R Inhibiting Monoclonal Antibodies
|
|
II. Clinical Trial Data for Novel and Emerging Therapies for the Management of Patients With Sjögren's Disease
|
|
III. Advances in Individualized Treatment Plans to Improve Outcomes in Patients With Sjögren's Disease
a.Symptom Management
b.Assessing and Monitoring Disease Progression and Impact on Patient QoL
|